



Continuation of Substance of Interview including description of the general nature of what was discussed: Indicated to Mr. Soller that claims 21 and 22 may be rejoined for allowance. Further indicated to Mr. Soller that claims 12, 17, 21, and 22 need to be amended to clarify that the label for each one of the first antibody and the second antibody of the claimed reagent mixture and kit are different and distinguishably distinct from the other by flow cytometry. Mr. Soller gave the Office authorization to amend claims 12, 17, 21 and 22 in Examiner's Amendment.